诱导多能干细胞
生物
多巴胺
帕金森病
疾病
神经元
神经科学
干细胞
食品药品监督管理局
细胞
胚胎干细胞
细胞疗法
细胞生物学
药理学
内科学
医学
遗传学
基因
出处
期刊:Stem Cells and Development
[Mary Ann Liebert, Inc.]
日期:2018-05-23
卷期号:27 (14): 958-959
被引量:29
标识
DOI:10.1089/scd.2018.0107
摘要
In 2012, we planned a program to develop a neuron replacement therapy for Parkinson's disease (PD) that would have the greatest promise to help the patients. PD is a movement disorder caused by the progressive, inevitable loss of a specific type of dopamine neuron in the brain. The only viable treatment to reverse the progress of the disease is to replace those neurons; we decided to make dopamine neurons that matched the patients, by differentiating induced pluripotent stem cells that we generated from individuals with PD. This autologous cell therapy is entering the regulatory approval process this year with the U.S. Food and Drug Administration to begin to transplant the cells in the following 1 to 2 years.
科研通智能强力驱动
Strongly Powered by AbleSci AI